| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17:46 | 500,000 patients' data for sale online after UK Biobank breach | ||
| 12:47 | Sanofi receives FDA approval for Tzield in paediatric diabetes | ||
| 11:46 | AbbVie opts for North Carolina to house $1.4bn manufacturing site | ||
| 10:46 | MSD teams up with Google Cloud on agentic AI transformation | ||
| Mi | Medicare weight loss drug pilot on ice as insurers decline to contribute | ||
| Mi | MSD-backed Ray locks in $125m to back eye drug pipeline | ||
| Mi | FDA approves MSD's once-daily HIV combo Idvynso | ||
| Mi | BioAegis and Prenosis partner for inflammatory disease therapies | ||
| Mi | Health Canada approves Biocon's two denosumab biosimilars | ||
| Di | Eli Lilly doubles down on in vivo with $7bn Kelonia buyout | ||
| Di | Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy | ||
| Di | Asahi Kasei acquires German company Aicuris | ||
| Mo | British patients risking "fake" weight loss drugs, despite safety concerns, survey says | ||
| Mo | Boehringer Ingelheim launches AI centre in London | ||
| Mo | Trump backs psychedelics for mental health in new executive order | ||
| Mo | UCB to purchase Neurona and NRTX-1001 for $1.15bn | ||
| Mo | MSD secures EC approval for Enflonsia to prevent infant RSV infection | ||
| Fr | Kailera makes history with record-breaking $625m IPO | ||
| Fr | Aligos and Xiamen Amoytop sign deal for HBV therapy | ||
| Fr | Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions | ||
| 16.04. | Developers back Alzheimer's drugs despite report suggesting lack of efficacy | ||
| 16.04. | Lilly debuts more Foundayo data as FDA requests post-marketing trials | ||
| 16.04. | Terremoto wins $108m in Series C to drive cancer and rare disease programmes | ||
| 16.04. | Nucleai and Sirona Dx to provide new proteomics solution for pharma companies | ||
| 16.04. | Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study |